Kori Williams
Primary Care · Bakersfield, CANPI 1013457969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,830, 5.5 times the $691 reported in 2021. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 456 payments — averaging $25.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$1K
- Amgen$940
- Corcept Therapeutics$702
- Lilly USA, LLC$660
- Xeris Pharmaceuticals, Inc.$653
- plus $5K from 40 others
What the payments were for
- Travel & lodging$8267%
- Food & beverage$10,64292%
- Education$570%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,150
- Korlym$368
- TEPEZZA$300
- RECORLEV$250
- EVENITY$250
- ISTURISA$133
- CeQur Simplicity$130
- Kerendia$111
- Yorvipath$109
- ZENPEP$104
How this compares
$11,525 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 585 | $576,612 |
| TymlosAbaloparatide | 75 | $249,766 |
| JardianceEmpagliflozin | 217 | $196,320 |
| TrulicityDulaglutide | 184 | $190,018 |
| MounjaroTirzepatide | 135 | $147,248 |
| FarxigaDapagliflozin Propanediol | 120 | $108,761 |
| ForteoTeriparatide | 25 | $108,207 |
| ProliaDenosumab | 42 | $70,806 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $36,532 |
| RybelsusSemaglutide | 27 | $34,469 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $28,151 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $27,901 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 74 | $26,384 |
| WegovySemaglutide | 18 | $25,484 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $24,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,338 | $636,564630 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Baqsimi | $660 | $452,686357 claims |
| Radius Health, Inc.Tymlos | $284 | $249,76675 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $390 | $224,245248 claims |
| AstraZenecaFarxiga | $53 | $108,761120 claims |
| AmgenProlia, Evenity (2 Syringes) | $940 | $98,95754 claims |
| BayerKerendia | $270 | $14,49919 claims |
| AbbVieSynthroid | $192 | $4,18650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Bakersfield
- Tyson FieldstedBakersfield$65K
- Lisa VelasquezBakersfield$4K
- Sara StarkBakersfield$3K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.